Table 3.
Statistics for serum concentrations of bone biomarkers in both groups in the study period
| Treatment group (N = 17) | P value | Control group (N = 14) | P value | |||||
|---|---|---|---|---|---|---|---|---|
| Baseline | 3 months | 6 months | Baseline | 3 months | 6 months | |||
| Homocysteine (μmol/L) | 11.70 ± 6.63 | 11.52 ± 4.47 | 10.17 ± 4.09 | 0.226 | 14.07 ± 3.60 | 14.50 ± 4.78 | 13.21 ± 4.54 | 0.266 |
| CI 95% | 8.55-14.85 | 9.40-13.65 | 8.23-12.12 | 12.18-15.96 | 11.99-17.00 | 10.83-15.59 | ||
| Vit B12 (Pg/ml) | 745.70 ± 623.07 | 517.17 ± 260.77 | 655.17 ± 460.18 | 0.189 | 435.75 ± 245.25 | 375.50 ± 475.02 | 235.42 ± 57.96 | 0.173 |
| CI 95% | 449.51-1041.89 | 393.21-641.14 | 436.42-873.94 | 307.69-564.23 | 126.66-624.33 | 205.70-265.79 | ||
| OC (ng/ml) | 15.34 ± 6.94 | 14.10 ± 6.13 | 13.84 ± 4.87 | 0.384 | 15.66 ± 9.99 | 16.71 ± 9.92 | 17.70 ± 10.03 | 0.460 |
| 95% CI | 12.03-18.64 | 11.18-17.02 | 11.53-16.16 | 10.43-20.90 | 11.51-21.91 | 12.44-22.96 | ||
| BALP (U/L) | 29.94 ± 11.02 | 30.82 ± 9.66 | 31.74 ± 9.30 | 0.614 | 31.17 ± 11.90 | 32.14 ± 14.35 | 34.46 ± 15.10 | 0.326 |
| 95% CI | 24.70-35.19 | 26.23-35.42 | 27.33-36.17 | 24.94-37.41 | 24.62-39.66 | 26.55-42.37 | ||
| UPYD (μg/mmol cr) | 42.99 ± 11.67 | 47.18 ± 9.99 | 46.61 ± 17.60 | 0.369 | 43.61 ± 11.14 | 45.11 ± 11.04 | 51.26 ± 15.56 | 0.107 |
| 95% CI | 37.44-48.54 | 42.43-51.93 | 38.25-54.99 | 37.78-49.45 | 39.32-50.90 | 43.11-59.41 | ||
| U β cross laps (μg/mmol cr) | 2.45 ± 1.58 | 2.43 ± 1.22 | 2.77 ± 1.86 | 0.358 | 3.10 ± 1.75 | 3.25 ± 1.92 | 3.68 ± 2.40 | 0.398 |
| 95% CI | 1.70-3.20 | 1.85-3.01 | 1.90-3.66 | 2.18-4.03 | 2.24-4.27 | 2.42-4.94 | ||
All data are presented as Mean ± SD. CI = confidence interval; Vit B12 = vitamin B12; OC = osteocalcin; BALP = bone alkaline phosphatase; UPYD = urine pyridinium cross links; U β cross laps = urine β cross laps.